Compliance takeaways from FDA’s final ‘intended use’ rule


The U.S. Food and Drug Administration’s “intended use” final rule reaffirms the agency’s wide latitude of discretion in establishing an off-label use case against pharmaceutical and medical device companies.

lock iconTHIS IS MEMBERS-ONLY CONTENT. To continue reading, choose one of the options below.